Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05414981 | A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection | PHASE1 | COMPLETED | 31 | — | — | Aug 7, 2022 | Apr 24, 2023 | Jun 29, 2023 | 9 | Bulgaria, Hong Kong +4 |
| Arm | Type | Description |
|---|---|---|
| ABI-H3733 | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABI-H3733 | DRUG | 25 mg or 100 mg tablets for oral administration |
| Placebo | DRUG | 25 mg or 100 mg tablets for oral administration |
Inclusion Criteria: 1. Body mass index (BMI) ≥ 18.0 and \< 35.0 kg/m(2), where BMI = weight (kg)/(height \[m\])(2) with a minimum body weight of 45 kg. 2. Chronic hepatitis B infection, defined as HBV infection for ≥6 months documented 3. Treatment-naïve or off-antiviral therapy for ≥24 weeks prior...